BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Recommendation of “Hold” by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given a consensus recommendation of “Hold” by the eleven ratings firms that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $9.07.

A number of equities analysts have recently commented on BCRX shares. Royal Bank of Canada reaffirmed a “buy” rating on shares of PrairieSky Royalty in a report on Friday, May 24th. JMP Securities cut their price target on BioCryst Pharmaceuticals from $18.00 to $10.00 and set an “outperform” rating for the company in a report on Thursday, May 23rd. HC Wainwright began coverage on in a report on Wednesday, May 22nd. They issued a “buy” rating for the company. BidaskClub raised YY from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, Jefferies Financial Group dropped their price objective on BioCryst Pharmaceuticals from $13.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 22nd.

In other BioCryst Pharmaceuticals news, CFO Thomas R. Staab II sold 7,750 shares of BioCryst Pharmaceuticals stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $7.30, for a total transaction of $56,575.00. Following the completion of the sale, the chief financial officer now owns 140,426 shares of the company’s stock, valued at $1,025,109.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Thomas R. Staab II sold 19,500 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $7.70, for a total value of $150,150.00. Following the sale, the insider now directly owns 142,426 shares of the company’s stock, valued at approximately $1,096,680.20. The disclosure for this sale can be found here. Insiders have sold 67,500 shares of company stock valued at $517,223 in the last three months. 5.20% of the stock is owned by corporate insiders.



Hedge funds have recently modified their holdings of the business. Spark Investment Management LLC bought a new stake in BioCryst Pharmaceuticals during the first quarter worth about $392,000. Paloma Partners Management Co bought a new stake in BioCryst Pharmaceuticals during the fourth quarter worth about $84,000. Bank of New York Mellon Corp lifted its stake in BioCryst Pharmaceuticals by 29.0% during the fourth quarter. Bank of New York Mellon Corp now owns 543,026 shares of the biotechnology company’s stock worth $4,383,000 after purchasing an additional 122,201 shares during the last quarter. JGP Global Gestao de Recursos Ltda. lifted its stake in BioCryst Pharmaceuticals by 8.5% during the first quarter. JGP Global Gestao de Recursos Ltda. now owns 25,742 shares of the biotechnology company’s stock worth $210,000 after purchasing an additional 2,018 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in BioCryst Pharmaceuticals by 69.7% during the fourth quarter. Principal Financial Group Inc. now owns 30,180 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 12,400 shares during the last quarter. 91.98% of the stock is owned by hedge funds and other institutional investors.

Shares of BioCryst Pharmaceuticals stock traded up $0.02 during trading hours on Tuesday, reaching $3.60. The company had a trading volume of 760,928 shares, compared to its average volume of 1,582,826. BioCryst Pharmaceuticals has a one year low of $2.80 and a one year high of $9.95. The business has a fifty day moving average price of $3.54. The company has a debt-to-equity ratio of 2.38, a current ratio of 1.77 and a quick ratio of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.28) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.28). BioCryst Pharmaceuticals had a negative return on equity of 223.34% and a negative net margin of 472.12%. The firm had revenue of $5.89 million during the quarter, compared to analyst estimates of $2.92 million. Sell-side analysts expect that BioCryst Pharmaceuticals will post -1.21 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Read More: What does an outperform rating mean?

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.